SK Biopharm holds sales meeting for marketing Cenobamate in US

The S.Korean pharmaceutical company will strengthen sales of its epilepsy drug targeting US medical staff and patients

SK Biopharm's sales meeting in San Diego 
SK Biopharm's sales meeting in San Diego 
Jae-Young Han 1
2023-02-16 10:18:25 jyhan@hankyung.com
Bio & Pharma

On Wednesday, SK Biopharmaceuticals Co. announced that its US subsidiary, SK Life Sciences Inc., held a "National Sales Meeting" in San Diego.

The purpose of the event is to motivate sales organizations and share future visions among US pharmaceutical companies.

Since the release of Cenobamate, an epilepsy treatment, in the United States in 2020, SK Biopharm has held a national sales meeting annually.

The company claims to be the only South Korean drug company to organize such an event.

"This year, we will be able to enhance our potential and achieve sustainable growth by targeting sales towards local medical staff and patients who have not previously used Cenobamate," said Lee Dong-hoon, CEO of SK Biopharmaceuticals.

Write to Jae-Young Han at jyhan@hankyung.com
#SK Biopharmaceuticals #SK Life Sciences #National Sales Meeting #korea sk biopharm cenobamate #sk biopharm sales meeting san diego

SK Biopharm begins clinical trials of wearable device for detecting epilepsy

SK Biopharm begins clinical trials of wearable device for detecting epilepsy

Hwang Sun-kwan, vice president of SK Biopharm SK Group's new drug development subsidiary SK Biopharmaceuticals Co. will begin clinical trials for a wearable device that can detect and predict epilepsy seizures in Korea early next year. As early as two to three years from now, the company plans

SK Biopharmaceuticals launches epilepsy drug in France

SK Biopharmaceuticals launches epilepsy drug in France

SK Biopharm's Cenobamate South Korean SK Biopharmaceuticals Co. said on Friday that its treatment of epilepsy "Cenobamate" has been approved for sale in France.The company launched the same drug in 15 European countries, beginning with Germany in June this year. The local drug brand name is "On

SK Biopharma's epilepsy treatment posts impressive growth in US

SK Biopharma's epilepsy treatment posts impressive growth in US

SK Biopharm researchers South Korean SK Biopharmaceuticals' epilepsy treatment Cenobamate has seen rapid growth on the US market.The company on Thursday said the medication's sales in the first three quarters hit 119.4 billion won ($89 million), with the third quarter alone seeing growth o

SK Biopharmaceuticals to make CES debut in January

SK Biopharmaceuticals to make CES debut in January

The researchers of SK Biopharmaceuticals (The courtesy of SK Biopharmaceuticals) SK Biopharmaceuticals will take part in CES 2023, the world's largest trade show for IT and electronics held in Las Vegas, to unveil its medical device for detecting signs of an epileptic seizure.The company will b
(* comment hide *}